US20070207139A1

US20070207139A1 - Enhancing the effect of therapeutic proteins on the central nervous system

Info

Publication number: US20070207139A1
Application number: US11/614,970
Authority: US
Inventors: Shunji Tomatsu; Adriana Montano; Tatsuo Nishioka; Jeffrey Grubb; William Sly; Monica Gutierrez; Amelia Rodriguez
Original assignee: St Louis University
Current assignee: St Louis University
Priority date: 2004-06-10
Filing date: 2006-12-21
Publication date: 2007-09-06
Also published as: US20100158889A1; US8226940B2

Abstract

The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human β-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient.

Description

PARENT CASE TEXT

This application claims benefit of priority to a continuation in part of U.S. application Ser. No. 11/245,424, filed Oct. 7, 2005, and also a continuation in part of U.S. application Ser. No. 10/864,758, filed Jun. 10, 2004.
Sequence Listing
A paper copy of the sequence listing and a computer readable form of the same sequence listing are disclosed in U.S. application Ser. No. 11/245,424, filed Oct. 7, 2005 to which this application claims benefit of priority as a continuation in part, and is herein incorporated by reference.

GOVERNMENT SUPPORT CLAUSE

This work was supported by the National Institutes of Health grant number GM34182, and International Morquio Organization. U.S. Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates to endowing therapeutic protein agents with increased in vivo stability and effectiveness on the central nervous system (CNS). More specifically, the present invention relates to endowing β-glucuronidase protein (GUS) with improved stability in the blood and enhanced ability to affect the CNS, in a therapeutic capacity by attaching a short peptide of acidic amino acids to the N-terminus of the protein.
2. Description of the Related Art
Lysosomal storage diseases (LSDs) are a class of forty rare genetic disorders, each of which is caused by a deficiency in a specific lysosomal enzyme. As a consequence of the progressive accumulation of unmetabolized macromolecules in the lysosomes of cells in various tissues, the disease manifestations worsen over time.¹Individuals afflicted with an LSD can suffer from mild to severe physical and/or neurological abnormalities or can die at an early age. A therapeutic paradigm for the treatment of LSDs was established with the success of enzyme-replacement therapy (ERT) for the treatment of Gaucher disease.^2,3In the case of Gaucher disease, delivery of the enzyme to the affected cells was achieved by modifying the N-linked carbohydrate on the enzyme. This exposed core mannose residues,^4,5enabling the enzyme to bind to the MR, which is highly abundant on cells of the reticuloendothelial system.^6,7These findings led to clinical management of Gaucher disease by ERT.⁸Over 3,500 patients have been treated with dramatic clinical results.⁹
Meanwhile there is a problem that pharmaceutical preparations of physiologically active proteins like enzymes and peptide hormones are generally made unstable when they are administered to the body, and thus undergo relatively rapid inactivation by, e.g., enzymatic degradation. For pharmaceutical preparations of a physiologically active protein, a method for increasing the stability of the physiologically active protein in the body is known which is based on coupling the proteins to polyethylene glycol.¹⁰
Sly's syndrome is an autosomal recessive, genetic lysosomal storage disease caused by an anomaly in the gene for a lysosomal enzyme, β-glucuronidase (hereinafter referred to as GUS) ¹¹(6), and is classified as type VII mucopolysaccharidosis (hereinafter referred to as MPS VII). In lysosomes, GUS acts as an exoglycosidase to remove glucuronic acid residues from the non-reducing termini of GAGs (glycosaminoglycans), such as dermatan sulfate (DS), heparan sulfate (HS), and chondroitin sulfate (CS). In the absence of GUS, GAGs are only partially degraded and accumulate in lysosomes of a variety of tissues. Progressive accumulation of undegraded GAGs in lysosomes affects the spleen, liver, kidney, cornea, brain, heart valves, and the skeletal system, leading to facial dysmorphism, growth retardation, systemic bone dysplasia, deafness, mental retardation, and shortened lifespan.
No effective remedy is currently available for MPS VII. Enzyme replacement therapy (ERT) has been considered to be the potential remedy for MPS VII. Considering its rapid inactivation in the body, however, native GUS is not expected to give any satisfactory effect.
The challenge is to improve joint and brain-related pathology since most of the enzyme-based drugs are delivered to major visceral organs like liver and spleen and only a small amount of enzyme is delivered to bone and brain. Many lysosomal enzymes have a short half-life when injected into the bloodstream because of rapid clearance in the liver by carbohydrate-recognizing receptors, particularly the mannose receptor that is highly abundant on Kupffer cells.¹²Although a part of the enzyme reaches the bone marrow, there is no way to guarantee that the enzyme will reach the brain since the blood brain barrier presents a formidable obstacle. As a result, current ERT doses not work efficiently on the bone and brain lesions.
The inventors have sought to address the problem of stability of therapeutic proteins in vivo and the inability of some proteins to effectively cross the blood brain barrier. The inventors have previously disclosed the use of short peptides of acidic amino acids to target proteins to bone tissue for use in Enzyme Replacement Therapy (ERT).¹³The inventors have also disclosed the use of short peptides of acidic amino acids to improve stability of physiological active proteins in the blood.
The addition of 4-15 acidic amino acids to GUS results in an increase in molecular weight which generally, would not be expected to increase functional activity of proteins to the CNS. In fact, higher molecular weigh molecules are more effectively excluded from the brain by an ineffectual crossing the blood brain barrier. Similarly, an increase in the hydrophilic nature of a molecule is also thought to exclude molecules at the blood brain barrier. The inventors have made the surprising discovery that despite causing an apparent increase in molecular weight and increase in hydrophilic nature, the addition of an acid amino acid leader to GUS has allowed enhanced therapeutic benefits on the brain.

SUMMARY OF THE INVENTION

An object of the present invention is a method to increase in vivo stability of a physiologically active peptide or protein by the addition of a short acidic amino acid leader, and thereby increase its therapeutic effects on the CNS for treatment of CNS related disease.
Previously, the inventors made the unexpected discovery that N-acetylgalactosamine-6-sulfate sulfatase (GALNS), tissue-nonspecific alkaline phosphatase (TNSALP) and GUS with a short amino acidic peptide (AAA) attached to the N-terminus increased targeting and deposition of these enzymes to bone. They further discovered that GALNS and GUS, with this short acidic amino acidic peptide attached possessed improved in vivo stability in the blood. The inventors have now further discovered that AAA-GUS possessed improved functional activity to tissues of the CNS, when administered to a patient with MPS VII.
The addition of a short amino acidic peptide attached to the N-terminus of GUS or other physiology active proteins possessing CNS therapeutic activity will endow these molecules with enhanced therapeutic benefits for the treatment for patients with CNS disorders. Compared with native physiologically active GUS, the present invention described above provides a physiologically active fusion protein with increased stability in the blood and increased therapeutic effects on the brain when administered to a patient with MPS VII.
Therefore, an object of this invention is 1) a polypeptide therapeutic agent with increased benefits for the CNS, 2) a method of increasing beneficial effects on the CNS, of a protein or polypeptide possessing CNS therapeutic activity, by attaching a 4-15 acid amino acid leader through chemical modification or genetic engineering of a fusion protein and 3) a method of treatment for patients suffering from CNS related diseases with the afore mentioned preparation.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: is a schematic diagram illustrating pCXN vector and the cloning site in the vector for the cDNA encoding native GUS or the GUS fusion protein
FIG. 2: illustrates the steps for the construction of an expression vector for the production of the GUS and GUS fusion protein.
FIG. 3: is a graph showing the time profiles of the blood activity levels of native GUS and GUS fusion protein after they are intravascularly administered in an equivalent amount.
FIG. 4: shows light microscopy of neocortex from native GUS and D₆-GUS treated mice.
The cortical neuron, hippocampus, and glia cell sections show a reduction of storage (S) in D₆-GUS treated compared to GUS treated MPS VII mice.

DETAILED DESCRIPTION OF THE INVENTION

Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders (LSDs) caused by deficiency of the lysosomal enzymes needed to degrade glycosaminoglycans (GAGs).¹⁴In MPS, the undegraded GAGs are stored in lysosomes and/or secreted into the blood stream^15,16, and excreted in urine. MPS involve the deficiency of one of 11 enzymes needed for the stepwise degradation of DS, HS, KS, and/or CS.
ERT is an established means of treating MPS. However, improving bone and brain pathology is still an unmet challenge because only a small fraction of enzyme is delivered to bone and brain. Most of the enzyme-based drugs are delivered to major visceral organs like liver and spleen. Although some of the enzyme reaches bone marrow, only small amounts of the enzyme go to bone or brain. The blood brain barrier provides a formidable obstacle for enzymes to reach brain. Therefore, the improvement of bone and brain lesions is quite limited, even after long-term treatment with ERT. We have tested an acidic oligopeptide-based targeting system for delivery of enzymes to tissues in murine MPS IVA and VII models. This strategy is based on tagging a short peptide consisting of acidic amino acids (AAA) to the mature enzyme. The AAA-tagged enzyme had five to ten times prolonged blood clearance compared with the untagged enzymes. The tagged enzyme was delivered effectively to bone, bone marrow, and brain in MPS VII mice and was more effective in reversing the storage pathology than the untagged enzyme.
Others have shown therapeutic responses in brain of mouse models MPS VII, aspartylglycosaminuria and β-mannosidosis when higher doses and longer treatment with enzyme is made possible.^17,18,19These results indicate that when therapeutic enzyme is administered over a sufficient period, at doses higher than those used in conventional ERT trials such a therapeutic dose has a beneficial effect in an adult mouse. The present invention allows such beneficial effects to be achieved with the administration of less therapeutic enzyme.
Therefore, the present invention discloses 1) an enzyme with therapeutic benefits for the CNS whereby said benefits are enhanced by the attachment of an AAA sequence, 2) a method of attaching an acidic amino acid sequence to a therapeutic enzyme with benefits for the CNS so as to allow said benefits to be delivered to the CNS under conditions which would otherwise be ineffectual, 3) a method of treating a patient with an CNS related disease using the aforementioned AAA-therapeutic enzyme.
The inventors have previous disclosed AAA-GALNS which is hereby incorporated by reference.²⁰This reference discloses a fusion protein for the treatment of disease, and a method of increasing the stability of a therapeutic protein in blood and transfer of said protein to bone. More specifically the therapeutic protein is GALNS and the disease is Morquio disease.
The inventors have also previously disclosed an AAA-GUS, described in detail bellow, and herein incorporated by reference.²¹This reference discloses a fusion protein AAA-GUS for the treatment of disease with improved in vivo stability and a method for treating a patient with MPS VII.
The term “polypeptide therapeutic agent” refereed to in the present invention means any polypeptide, oligopeptide or protein which will benefit a patient suffering from disease when administered to the patient.
The term “acidic amino acid” or “AAA” referred to the present invention means glutamic acid or aspartic acid. As the employment of these acidic amino acids in the present invention is for the purpose of constructing an acidic short peptide, they may be used in any arbitrary combination including a simple use of one or the other of them alone for construction of such a short peptide. The number of the acidic amino acids forming a short peptide is preferably 4-15, more preferably 4-12, and still more preferably 4-8.
A short peptide consisting of acidic amino acids may be directly attached to the N-terminus of physiologically active human GUS via a peptide bond or like, or, instead, it may be attached via a linker peptide.
In the present invention “a linker peptide” is not an indispensable component, for it is usable only for convenience in attaching a short peptide consisting of acidic amino acids to N-terminus of physiologically active GUS. Where it is used, a linker peptide may be a short peptide consisting e.g., preferably of 15 or less, more preferably of 10 or less, and still more preferably of 6 or less amino acids. Such a linker that consists of a single amino acid molecule and linking between the acidic short peptide and physiologically active GUS via peptide bonds is also included in the definition of a linker peptide. A linker peptide may be made of any one or more amino acids desired.
In the present invention, though there is no specific limitation as to the method for attaching an acidic short peptide to physiologically active GUS, it is of advantage, e.g., to form and use a transformant cell expressing the fusion protein consisting of the short peptide and physiologically active GUS.
In the present invention “attachment” in reference to acidic amino acids or AAA and therapeutic proteins or peptides or enzymes refers to creation of a covalent bond either through the creation of a fusion protein or through the use of chemical agents or manipulation to achieve the same result.
A fusion protein of the present invention may include a non-acidic amino acid or a sequence of several (e.g., 3) non-acidic amino acids at N-terminus of the short peptide consisting of acidic amino acids.
A fusion protein of the present invention may be formulated into a pharmaceutical composition containing the fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier well known to those skilled in the art, for parenteral administration by e.g., intravenous, subcutaneous, or intramuscular injection or by intravenous drip infusion.
For pharmaceutical compositions for parenteral administration, any conventional additives may be used such as excipients, binders, disintegrants, dispersing agent, lubricants, diluents, absorption enhancers, buffering agents, surfactants, solubilizing agents, preservatives, emulsifiers, isotonizers, stabilizers, solubilizers for injection, pH adjusting agents, etc.
A fusion protein of the present invention may be used advantageously in place of the conventional native enzyme protein in a substitution therapy for the treatment of MPS VII. In the treatment, the fusion protein may be administered intravenously, subcutaneously, or intramuscularly. Doses and frequencies of administration are to be determined by the physician in charge in accordance with the condition of his or her patient.
Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims, which follow the examples.

EXAMPLE 1

Method for Construction of Expression Vectors

Vector pCXN had been constructed in accordance with a literature (7) and was offered to us by Prof. Miyazaki at Osaka University. An expression vector for native human GUS, pCXN-GUS, was constructed by using human GUS cDNA that had been reported by Oshima et al. (8)(Accession No. of GenBank for the Amino acid and cDNA sequence of Human GUS is BC014142.). An expression vector for human GUS to the N-terminus of which is attached (via a linker peptide) a short peptide (N-terminal bone tag: NBT) consisting of acidic amino acids (NBT-GUS), was constructed starting with pCXN-GUS in the following manner. FIGS. 1 and 2 schematically illustrate the process for construction.
Using pCXN-GUS as a template, PCR was carried out using LA-Taq (Takara) to amplify Δsig GUS cDNA (the sequence, nt 67-1956, left behind after removal of the sequence of nt 1-66 corresponding to a secretion signal, from the ORF region of the sequence set forth as SEQ ID NO:1) (for human GUS without signal sequence, see SEQ ID NO:2), to the 5′-terminus of which is attached an AgeI cleavage sequence. The PCR was carried out according to the instruction for use of LA-Taq, i.e., through the cycles consisting of 30 seconds at 94° C., (30 seconds at 94° C., 30 seconds at 60° C., and 2 minutes at 72° C.)×25, and then 3 minutes at 72° C., with primer 1 (SEQ ID NO:3), and primer 2 (SEQ ID NO:4). The cDNA thus amplified was inserted into pT7Blue vector (Novagen) to construct pT7-Δsig GUS.
The N-terminal bone tag (NBT) cDNA to be attached to the 5′-terminus then was constructed by PCR using LA-Taq (Takara). Briefly, primer 3 (SEQ ID NO:5) and primer 4 (SEQ ID NO:6) were used for the construction of NBT-E6 cDNA, primer 5 (SEQ ID NO:7) and primer 4 (SEQ ID NO:6) for the construction of NBT-E8 cDNA, primer 6 (SEQ ID NO:8) and primer 4 (SEQ ID NO:6) for the construction of NBT-D6 cDNA, and primer 7 (SEQ ID NO:9) and primer 4 (SEQ ID NO:6) for the construction of NBT-D8 cDNA. In the names of the NBT cDNAs, “E6” or “E8” indicate that the NBT is made up of 6 or 8 serially connected glutamic acid residues, respectively. Likewise, “D6” or “D8” indicates that the NBT is made up of 6 or 8 connected aspartic acid residues, respectively.
Employing each pair of the above primers, which contained a portion complementary to each other, PCR was carried out through the cycles consisting of 30 seconds at 94° C., (30 seconds at 94° C., 30 seconds at 60° C., 30 seconds at 72° C.)×20 minutes, and then one minute at 72° C. The thus amplified DNA fragments were inserted into pT7Blue vector (Novagen) to construct pT7-NBTs.
A human GUS cDNA recovered as a fragment of pT7 pT7-Δsig GUS cleaved with AgeI and XbaI was inserted into the AgeI-XbaI site of pT7-NBTs to construct pT7-NBT-GUSs.
Then each of pT7-NBT-GUSs was cleaved with BclI, blunt-ended with T4 DNA polymerase, and cleaved with XbaI to recover NBT-GUS cDNAs.
pST-RAP-GUSB (a vector comprising the p97 signal sequence, provided by Tomatsu at Saint Louis University) was cleaved with BamHI and XbaI, into which then was inserted the NBT-GUS cDNAs recovered above to construct pST-p97-NBT-GUSs.
pST-p97-NBT-GUSs were cleaved with EcoRI to recover respective p97-NBT-GUS cDNAs, each of which then was inserted into the EcoRI site of pCXN to construct a NBT-GUS expression vector, pCXN-p97-NBT-GUS. The DNA sequence of the expression vectors' region corresponding to the p97-NBT-D6-GUS, p97-NBT-D8-GUS, p97-NBT-E6-GUS and p97-NBT-E8-GUS cDNAs are shown in the Sequence Listing (SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16,) along with their corresponding amino acid sequences (SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17), respectively.
SEQ ID NO:10 shows part of the sequence containing the NBT-E6-GUS cDNA of pCXN-p97-NBT-E6-GUS. Its nt 1-57 encode the p97 signal sequence, nt 61-78 a poly Glu, nt 79-96 a linker sequence, and nt 97-1983 GUS without the signal sequence.
SEQ ID NO:11 shows the NBT-E6-GUS amino acid sequence with the p97 signal sequence. Aa 1-19: p97 signal sequence, aa 21-26: poly Glu, aa 27-32: linker sequence, aa 33-661: GUS without signal sequence.
SEQ ID NO:12 shows part of the sequence containing the NBT-E8-GUS cDNA of pCXN-p97-NBT-E8-GUS. Its nt 1-57 encode the p97 signal sequence, nt 61-84 a poly Glu, nt 85-102 a linker sequence, and nt 103-1989 GUS without the signal sequence.
SEQ ID NO:13 shows the NBT-E8-GUS amino acid sequence with attached p97 signal sequence. Aa 1-19: p97 signal sequence, aa 21-28: poly Glu, aa 29-34: linker sequence, aa 35-663: GUS without signal sequence.
SEQ ID NO:14 shows part of the sequence containing the NBT-D6-GUS cDNA of pCXN-p97-NBT-D6-GUS. Its nt 1-57 encode the p97 signal sequence, nt 61-78 a poly Asp, nt 79-96 a linker sequence, and nt 97-1983 GUS without the signal sequence.
SEQ ID NO:15 shows the NBT-D6-GUS amino acid sequence with attached p97 signal sequence. Aa 1-19: p97 signal sequence, aa 21-26: poly Asp, aa 27-32: linker sequence, aa 33-661: GUS without signal sequence.
SEQ ID NO:16 shows part of the sequence containing the NBT-D8-GUS cDNA of pCXN-p97-NBT-D8-GUS. Its nt 1-57 encode the p97 signal sequence, nt 61-84 a poly Asp, nt 85-102 a linker sequence, and nt 103-1989 GUS without the signal sequence.
SEQ ID NO:17 shows the NBT-D8-GUS amino acid sequence with attached p97 signal sequence. Aa 1-19: p97 signal sequence, aa 21-28: poly Asp, aa 29-34: linker sequence, aa 35-663: GUS without signal sequence.
The proteins set forth as SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17 contain the p97 secretion signal sequence. The signal sequence is removed during secretion process from the cell and the fusion proteins are thus recovered as NBT-GUS in the medium.
p97 is a cell-surface glycoprotein occurring in most human melanomas and its signal sequence consists of 19 amino acids(9). The aforementioned pCXN-p97-NBT-GUSs containing the cDNA encoding this signal sequence may also be constructed by the following method. Briefly, a cDNA containing the p97 signal sequence is synthesized through the process of primers annealing and PCR amplification. LA-Taq is used as an enzyme for PCR. As primers having mutually complementary portions, primer 8 (SEQ ID NO:18) and primer 9 (SEQ ID NO:19) are used. PCR is performed through the cycles of 30 seconds at 94° C., (30 seconds at 94° C., 30 seconds at 60° C., 30 seconds at 72° C.)×20, and one minute at 72° C. The amplified cDNA containing the p97 signal sequence is cleaved with BamHI and EcoRI. Into the pCXN vector, after cleaved with EcoRI, are simultaneously incorporated the aforementioned NBT-GUSs cDNA recovered after the enzyme treatment and cDNA for the p97 signal sequence, giving pCXN-p97-NBT-GUSs.
SEQ ID No:18 is a forward primer, in which nt 1-5 comprise a random synthetic sequence, and nt 6-52 comprise part of the sequence encoding the p97 signal.
SEQ ID No:19 is a reverse primer, in which nt 1-6 comprise a random synthetic sequence, and nt 7-52 comprise part of the sequence encoding the p97 signal.
Establishment of Expression Cells
Nunclon delta-MultiDish 6 Well was inoculated with CHO-K1 cells. After an overnight culture in DMEM/F12/FBS medium [DMEM/F12 medium(Gibco) supplemented with 10% fetal bovine serum (Thermo Trace)], each of the expression vector constructed above was introduced into the cells using Lipofectamine 2000 reagent. For experimental procedures, the instruction manual attached to the Lipofectamine 2000 reagent was followed. After a two-day incubation at 37° C. in 5% CO₂, the cells were added to 75-cm²tissue culture flasks (Iwaki) and incubated until colonies of resistant cells were formed with Genetcin (Gibco) added to the DMEM/F12/FBS medium at the final concentration of 1 mg/mL. After formation of colonies was confirmed under a microscope, cells which exhibited stable expression were cloned by the limiting dilution-culture method. Screening for expression cells were performed by GUS-specific enzyme activity assay of the culture supernatants. Cell lines thus established were subcultured in DMEM/F12/FBS medium supplemented with 0.2 mg/mL Geneticin.
Method for Measurement of GUS-Specific Enzyme Activity
After intravenous administration of native-or NBT-GUS to mice, GUS activity in the blood was determined as follows. Briefly, 12.5 uL of plasma sample from the mice was added to 50 uL of a solution of 10 mM 4-methylumbelliferyl-β-D-glucuronide (Sigma Chemical Co., St. Louis, Mo., cat #M9130) which had been prepared using determination buffer (0.1M sodium acetate buffer pH 4.8), and reaction was allowed for 1 hr at 37° C. Then, 950 uL of stop buffer (1 M Glycine-HCl, pH 10.5) was added and mixed to stop the enzyme reaction. Samples of the reaction mixture were transferred to a fluorometer for measurement with excitation 366 nm/emission 450 nm.
Expression and Purification of Native GUS and GUS Fusion Protein
Native GUS and GUS fusion proteins were produced in overexpressing CHO cells, which were grown to confluency and fed with low-serum medium (Waymouth's MB 752/1 medium, supplemented with 2% FBS/1.2 mM glutamine/1 mM pyruvate) (Gibco) for purification every 24 hr. The media of the culture were pooled, centrifuged at 5,000×g for 20 min at 4° C., and frozen at −20° C. Purification was performed using affinity chromatography (10). Briefly, the conditioned medium from cells overexpressing the Native GUS or a GUS fusion protein was filtered, and NaCl was added to the medium at the final concentration of 0.5 M. The medium was applied to a 5 ml column of Affi-Gel 10 (BioRad) which carried an anti-human GUS monoclonal antibody and had been pre-equilibrated with wash buffer. The column was washed at 36 mL/hour with 20-column volumes of wash buffer. The column was eluted at 36 mL/hour with 50 ml of 10 mM sodium phosphate (pH 5.0) containing 3.5 M MgCl₂. Fractions were collected and subjected to GUS activity assay. Fractions containing the enzyme activity were pooled for each of the Native or fusion proteins, diluted with an equal volume of P6 buffer (25 mM Tris, pH 7.5/1 mM β-glycerol phosphate/0.15 mM NaCl/0.025% sodium azide), and desalted over a BioGel P6 column (BioRad) pre-equilibrated with P6 buffer. Fractions containing GUS activity were pooled, and the finally purified active protein was stored at −80° C.

EXAMPLE 2

Stability in the Blood

Per 1 g of body weight, 1,000 U of native GUS or one of the NBT-GUSs, both purified, were administered to male, 4-month old C57BL mice (3 animals/group) in the tail vein. Samples of venous blood were collected at 2 min, 5 min, 10 min, 20 min, 30 min, 1 hr, 2 hr, 6 hr, 24 hr after the administration, and GUS activity in the serum was measured. The results are shown in FIG. 3. Comparison between the NBT-GUSs-administered groups and the native GUS-administered group reveales that, at 2 min after the administration, the enzyme activity in the blood was 2-fold higher in the NBT-GUSs-administered groups as compared with the native GUS-administered group. While the enzyme activity in the blood at 30 min after the administration was almost disappeared in the native GUS-administered group, the NBT-GUSs-administered groups retained activity levels, which were even higher than the activity level found at 2 min in the native GUS-administered group. Afterwards, the NBT-GUSs-administered groups continued to show remarkably slower reduction in the enzyme activity levels in the blood as compared with those found in the native GUS-administered group. Even 24 hr (1440 min) after the administration, the residual enzyme activity was detectable in the NBT-GUSs-administered group. A half-life time of the enzyme activity in blood in the native GUS-administered group was 4.9 min, while a half-life time in blood in the NBT-GUS-administered group was prolonged 5-6 times. The results demonstrate that the stability of GUS in the body is remarkably increased by attaching a short peptide of acidic amino acids to the N-terminus of native GUS.

EXAMPLE 3

Effects of GUS on Brain Tissue

To compare the effectiveness of AAA-tagged and untagged GUS at clearing storage from affected tissues in the MPS VII mouse, the inventors used a protocol in which enzyme was given in 12 weekly treatments with 1 mg/kg enzyme. There were notable differences in which the D₆-GUS appeared to be more effective in clearing the storage material. The parietal neocortical neurons and glia had less storage in the D₆-GUS-treated MPS VII mice. In brain, the AAA-tagged enzyme showed improved clearance of storage from parietal neocortical neurons and glial cells, where as storage showed minimal or no clearance response to untagged enzyme at the same dose. FIG. 4 shows light microscopy of tissues from native GUS and D₆-GUS treated MPS VII mice. The cortical neuron, hippocampus, and glia cell sections show a reduction of storage (S) in D₆-GUS treated compared to GUS treated mice.
In these studies, MPS VII/E540A^tgmice were used.²²These mice carry a GUS transgene that encodes an inactive enzyme, which confers immunotolerance to the human protein. To define the clearance from the blood circulation, 1,000 units per g of body weight of D6-GUS, D8-GUS or untagged GUS were administered to 4-month-old MPS VII mice (3 animals/group) via the tail vein. Samples of venous blood were collected at 2 min, 5 min, 10 min, 20 min, 30 min, 1 h, 2 h, 6 h, and 24 h after administration, and GUS activity in the serum was measured.
To determine the effectiveness of D6-GUS, D8-GUS, and untagged enzyme at reversing storage pathology, three adult animals in each group received twelve weekly doses (5,000 units/g) of D6-GUS, D8-GUS, untagged enzyme or PBS by injection in the lateral tail vein.
Animals were killed 1 week after the 12th injection, and the organs were removed for histopathology analysis with light or electron microscopy.
For morphological evaluation, liver, spleen, kidney, brain, heart, femur, and bone marrow from 4-5 month old MPS VII mice treated with D6-GUS (n=2), D8-GUS (n=3), and untagged enzyme (n=3), or buffer (n=2) were collected at necropsy, immersion-fixed in 4% paraformaldehyde/2% glutaraldehyde in PBS, postfixed in osmium tetroxide, and embedded in Spurr's resin. For evaluation of lysosomal storage by light microscopy, toluidine blue-stained 0.5-μm-thick sections were examined. One mouse treated by D6-GUS died immediately after the 12th weekly infusion and was not evaluated morphologically. Tissues from the treated and untreated mice were evaluated for reduction in storage without knowledge of their treatment. Two pathologists (CV, BL) independently evaluated the brain for lysosomal storage.
Some individual elements of the inventors' methodology are generally known or described in detail in numerous laboratory protocols, one of which is Molecular Cloning 2nd edition, (1989) Sambrook, J., Fritsch, E. F. and Maniatis, J., Cold Spring Harbor. As such detailed discussion of their composition and methodology is superfluous.

REFERENCES

Applicants make no statement, inferred or direct, regarding the status of the following references as prior art. Applicants reserve the right to challenge the veracity of any statements made in these references, which are incorporated herein by reference.

¹Wraith, J. E. (2002) Semin. Neonatol. 7, 75-83.
²Barton, N. W., Furbish, F. S., Murray, G. J., Garfield, M. & Brady, R. O. (1990) Proc. Natl. Acad. Sci. USA 87, 1913-1916.
³Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., et al. (1991) N. Engl. J. Med. 324, 1464-1470.
⁴Murray, G. J. (1987) Methods Enzymol. 149, 25-42.
⁵Furbish, F. S., Steer, C. J., Krett, N. L. & Barranger, J. A. (1981) Biochim. Biophys. Acta 673, 425-434.
⁶Stahl, P. D., Rodman, J. S., Miller, M. J. & Schlesinger, P. H. (1978) Proc. Natl. Acad. Sci. USA 75, 1399-1403.
⁷Achord, D. T., Brot, F. E., Bell, C. E. & Sly, W. S. (1978) Cell 15, 269-278.
⁸Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I. & Argoff, C. E. (1991) N. Engl. J. Med. 324, 464-470.
⁹Barranger, J. A. & O'Rourke, E. (2001) J. Inherit. Metab. Dis. Suppl 2, 89-96.
¹⁰Japanese Patent No. 2852127
¹¹Sly W S, Quinton B A, McAlister W H, and Rimoin D L,. J Pediatr. 82:249-257 (1973)
¹²Achord, D. T., Brot, F. E., Bell, C. E. & Sly, W. S. (1978) Cell 15, 269-278.
¹³U.S. application Ser. No. 11/484,870, filed Jul. 11, 2006
¹⁴Neufeld E F, Muenzer J. (2001) The Mucopolysaccharidoses. In Scriver, C. R., Beaudet, A., Valle, D., and Sly. W. S. (eds.), The Metabolic and Molecular Bases of Inherited Diseases. 8th edition ed. McGraw-Hill Professional, New York, Vol. III, pp. 3421-3452.
¹⁵Tomatsu S, Okamura K, Taketani T, Orii K O, Nishioka T, Gutierrez M A, Velez-Castrillon S, Fachel A A, Grubb J H, Cooper A, Thornley M, Wraith E, Barrera L A, Giugliani R, Schwartz I V, Frenking G S, Beck M, Kircher S G, Paschke E, Yamaguchi S, Ullrich K, Isogai K, Suzuki Y, Orii T, Kondo N, Creer M, Noguchi A. (2005). J Inherit Metab Dis. 28:187-202.
¹⁶Tomatsu S, Gutierrez M A, Ishimaru T, Pena O M, Montano A M, Maeda H, Velez-Castrillon S, Nishioka T, Fachel A A, Cooper A, Thornley M, Wraith E, Barrera L A, Laybauer L S, Giugliani R, Schwartz I V, Frenking G S, Beck M, Kircher S G, Paschke E, Yamaguchi S, Ullrich K, Isogai K, Suzuki Y, Orii T, Noguchi A. (2005). 28:743-57
¹⁷Vogler, C., Levy, B., Grubb, J. H., Galvin, N., Tan, Y., Kakkis, E., Pavloff, N. & Sly W. S. (2005), Proc Natl Acad Sci USA. 102:14777-14782.
¹⁸Dunder, U., Kaartinen, V., Valtonen, P., Vaananen, E., Kosma, V. M., Heisterkamp, N., Groffen, J. & Mononen, I. (2000), FASEB J. 14, 361-367.
¹⁹Roces D P, Lullmann-Rauch R, Peng J, Balducci C, Andersson C, Tollersrud O, Fogh J, Orlacchio A, Beccari T, Saftig P, von Figura K. (2004), 13:1979-1988.
²⁰U.S. application Ser. No. 10/864,758, filed Jun. 10, 2004
²¹U.S. application Ser. No. 11/245,424, filed Oct. 7, 2005
²²Sly, W. S., Vogler, C., Grubb, J. H., Zhou, M., Jiang, J., Zhou, X. Y., Tomatsu, S., Bi, Y. & Snella, E. M. (2001), Proc. Natl. Acad. Sci. USA 98, 2205-2210.

Claims

1. A polypeptide therapeutic agent with increased central nervous system therapeutic activity comprised of a) a physiologically active protein with therapeutic benefits for the central nervous system, and b) a short peptide which consisting of 4-15 acidic amino acids attached to the physiology active protein via the N-terminus thereof.

2. A polypeptide therapeutic agent as in claim 1 wherein said physiologically active protein is an enzyme.

3. A polypeptide therapeutic agent as in claim 1 wherein said physiologically active protein is an enzyme known to be therapeutic in treatment of lysosomal storage disease.

4. A polypeptide therapeutic agent as in claim 1 wherein said physiologically active protein is human β-glucuronidase.

5. A polypeptide therapeutic agent as in claim 1 wherein attaching said acid amino acid sequence of 4-15 amino acids to the N terminus of said polypeptide increases clearance time in the blood.

6. A polypeptide therapeutic agent as in claim 1 whereby attached comprises produced a fusion protein through genetic engineering.

7. A polypeptide therapeutic agent as in claim 1 whereby attached comprises chemically linking at least two molecules.

8. A polypeptide therapeutic agent as in claim 1 whereby attached is via a linker peptide.

9. A method of increasing therapeutic benefits of a physiologically active protein on the central nervous system wherein the method comprises, a) a physiologically active protein with therapeutic benefits for the central nervous system, and b) a short peptide consisting of 4-15 acidic amino acids, which is c) attached to said physiology active protein via the N-terminus thereof.

10. A method of increasing therapeutic benefits as in claim 9 whereby said physiologically active protein is an enzyme.

11. A method of increasing therapeutic effects as in claim 9 whereby said physiologically active protein is an enzyme known to be therapeutic in treatment of lysosomal storage disease.

12. A method of increasing therapeutic effects as in claim 9 whereby said physiologically active protein is human β-glucuronidase.

13. A method of increasing therapeutic effects as in claim 9 whereby attaching said acid amino acid sequence of 4-15 amino acids to the N terminus of said polypeptide increases clearance time in the blood.

14. A method of increasing therapeutic effects as in claim 9 whereby attaching comprises a fusion protein produced through genetic engineering.

15. A method of increasing therapeutic effects as in claim 9 whereby attaching comprises chemically linking at least two molecules.

16. A method of increasing therapeutic effects as in claim 9 whereby attaching is via a linker peptide.

17. A method of treating a patient with a central nervous system disease by administering an effective amount of a physiologically active protein with therapeutic benefits for the central nervous system, and b) a short peptide which consists of 4-15 acidic amino acids, which is c) attached to the physiology active protein on the N-terminus thereof.

18. A method as in claim 17 whereby said physiologically active protein is human β-glucuronidase.

19. A method as in claim 17 whereby said central nervous system disease is a lysosomal storage disease.

20. A method as in claim 17 whereby said central nervous system disease is type VII mucopolysaccharidosis.

21. A method as in claim 17 whereby said physiologically active protein with said short peptide attached further comprises increased clearance time in the blood.